Globenewswireยท2025-09-25 17:21Core Viewpoint - Theratechnologies Inc. has completed a plan of arrangement under Quebec's Business Corporations Act, resulting in the acquisition of all its common shares by CB Biotechnology, LLC for US$3.01 per share in cash, plus contingent value rights (CVRs) that could yield up to an additional US$1.19 per share if certain milestones are met [1][4]. Group 1: Acquisition Details - The Purchaser has acquired all issued and outstanding common shares of Theratechnologies for US$3.01 per share in cash [1]. - Each CVR entitles the holder to additional payments of up to US$1.19 per CVR based on the achievement of specific milestones [3]. - The fair market value of each CVR has been determined to be US$0.80 as of September 24, 2025, according to an independent third-party valuation [3]. Group 2: Shareholder and Regulatory Actions - Payments for the shares will be made to former shareholders as soon as practicable after the completion of necessary documentation [2]. - Following the completion of the arrangement, Theratechnologies' shares are expected to be de-listed from the Toronto Stock Exchange and Nasdaq Capital Market on September 26 and 25, 2025, respectively [4]. - The Company will apply to cease being a reporting issuer under Canadian securities laws and will deregister its shares under the U.S. Securities Exchange Act of 1934 [4]. Group 3: Company Background - Theratechnologies is a commercial-stage biopharmaceutical company focused on innovative therapies that aim to redefine standards of care [6]. - Future Pak, the Purchaser's affiliate, is a privately held contract manufacturer and distributor of pharmaceutical and nutraceutical products, established in 1977 [7].